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Pheochromocytoma (PCC) and paraganglioma (PGL) are
the neuroendocrine tumours that arise in adrenal
medulla or extra adrenal sympathetic and parasympa-
thetic paraganglia. Paraganglia are small organs that
mainly consist of neuroendocrine cells derived from the
embryonic neural crest that have the ability to synthe-
size and secrete catecholamines. Sympathetic PGLs are
usually located in the chest, abdomen, or pelvis while
parasympathetic PGLs are distributed along parasympa-
thetic nerves in the head, neck, and upper mediastinum,
also referred to as head and neck PGL (HNP). PCC/
PGLs can be either functional (sympathetic) or non-
functional (parasympathetic) based on catecholamine
synthesis and secretion.
In children diagnosed with hypertension, up to 1.7%
have a catecholamine-secreting neoplasm. The majority
of these tumours in childhood are PCC/PGLs. Incidence
rates of PCC/PGLs are estimated at 0.3 cases per million
per year or less. Approximately 10 –20% of these cases
are diagnosed during childhood. Approximately half of
the apparently sporadic PCC/PGLs that present in
patients younger than 18 years are due to an identifiable
germline mutation and this increases up to 70% in chil-
dren less than 10 years of age. Hereditary tumor syn-
dromes associated with PCC include Von Hippel-Lindau
(VHL) disease, multiple endocrine neoplasia 2 (MEN-2),
the familial PGL syndromes and rarely, neurofibromato-
sis (NF) type 1. Recently, many other genes are found to
be involved in pathogenesis of PCC/PGLs. Hereditary
PCC/PGLs are often multifocal and, in the case of PCC,
frequently bilateral.
Children usually present becauseof symptomatic cate-
cholamine hypersecretion or, less often, due to tumor
mass effects (e.g. pain), or as an incidental radiographic
finding, or because of family screening. At present, the
diagnostic test of choice is the measurement of fractio-
nated plasma and/or urine metanephrines (metane-
phrines and normetanephrines). A four-fold increase
above the reference range is associated with an almost
100% probability of the presence of a catecholamine-
secreting tumor.
123I-metaiodobenzylguanidine(MIBG) is a highly speci-
fic test that can confirm the catecholamine-secreting
nature of a tumor, localize tumors not seen with cross-
sectional imaging, and identify other sites of disease as
well as metastasis. Because MIBG testingis not 100%
sensitive, particularly in some genetic mutations,
recently other functional scans have been studied in the
evaluation of PCC/PGL: 18F fluorodihydroxyphenylala-
nine (DOPA) positron emission tomography (PET), 18F
fluorodopamine (FDA) PET,18F fluorodeoxyglucose
(FDG) PET.
Surgical resection is the mainstay in the treatment of
PCC/PGLs. It should be done after adequate alfa and
beta adrenergic blockade to minimize the hemodynamic
fluctuation during surgery. Laparoscopic adrenalectomy
is the preferred procedure for most PCC. Laparotomy
should be considered in patients with large PCC and/or
a concern for underlying malignancy based upon the
clinical presentation or radiographic appearance of the
tumor. In the setting of bilateral PCC, cortical-sparing
procedures should be considered for the adrenal with
the least tumor bulk. The cortical-sparing approach is
particularly attractive in young children and children at
risk for noncompliance with lifelong glucocorticoid and
mineralocorticoid replacement. The surgical approach
for removal of a PGL depends upon the location of the
tumor but in selected cases can also be performed
laparoscopically.
Patients with unresectable malignant tumors or distant
metastatic disease can usually be treated symptomati-
cally with adrenergic blockade. Radiation therapy or
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radiofrequency ablation can help with symptomatic
metastatic disease, and IV bisphosphonates can be con-
sidered bony metastases, particularly in patients with
bone pain or lesions that increase the risk of pathologi-
cal fracture. Systemic treatment modalities are only pal-
liative in nature and include 123I-MIBG therapy, peptide
receptor radiotherapy (PRRT) and chemotherapy. PCC/
PGLs can have unpredictable behavior and metastasize
late in the clinical course. In addition, children in parti-
cular are at risk for the development of metachronous
tumors. This makes long-term follow-up mandatory in
children with PCC/PGL.
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